Immunology of Ebola Vaccine
NCT06100913 is a phase 2 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is active and no longer recruiting. It studies Recombinant Vesicular Stomatitis Vaccine for Ebola in Ebola Virus Disease. The registry lists an enrollment of 30 participants at 2 sites in 1 country. The registry lists a start date of 6 Aug 2024 and a primary completion date of 31 Aug 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06100913 |
| Status | Active not recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Emory University |
| Enrollment | 30 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Ebola Virus Disease |
| Drugs | Recombinant Vesicular Stomatitis Vaccine for Ebola |
| Start | 6 Aug 2024 |
| Primary completion | 31 Aug 2027 |
| Study completion | 31 Aug 2027 |
| Last update posted | 22 Jan 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Ali Ellebedy, PhD
Washington University School of Medicine
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Hope Clinic of the Emory Vaccine Center
Decatur
- Washington University in St. Louis
St Louis
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06100913
Each answer restates registry values shown on this page.
What is NCT06100913?
NCT06100913 is a phase 2 interventional trial sponsored by Emory University. It studies Recombinant Vesicular Stomatitis Vaccine for Ebola in Ebola Virus Disease.
Is NCT06100913 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT06100913?
The registry names Ali Ellebedy, PhD (study chair, Washington University School of Medicine) and Nadine Rouphael, MD (principal investigator, Emory University) as overall officials.
Where does NCT06100913 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06100913 study?
The registered drug and biological interventions are Recombinant Vesicular Stomatitis Vaccine for Ebola.
When is NCT06100913 expected to complete?
The registry lists a primary completion date of 31 Aug 2027 and a study completion date of 31 Aug 2027. The sponsor last updated the record on 22 Jan 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.